Sandisk rallies on AI demand while Meta's Muse release triggers a sell-off in travel and telecom stocks, and Immunovant halts a key drug program after a clinical trial miss.
Immunovant is halting development of its lead drug candidate imeroprubart in skin lupus following a trial miss.
Sandisk shares are up 644% this year and the article indicates further upside driven by artificial-intelligence-fueled demand.
Meta's release of Muse AI has disrupted competing consumer platforms, likely strengthening Meta's competitive position.
Expedia was among online travel booking platforms dropping on Wednesday due to disruption from Meta's Muse release.
AT&T shares are being hit by worries that Meta's Muse release will hurt consumer businesses.
McDonald's announced a multi-billion-dollar investment to upgrade menus, restaurants, and service, but the stock slipped Wednesday.
Sandisk shares have climbed 644% this year, fueled by robust demand for artificial intelligence infrastructure. Meanwhile, broader markets face volatility as Meta's new Muse AI release disrupts consumer-facing sectors, pressuring stocks like AT&T and Expedia. Additionally, Immunovant shares face headwinds following a failed drug trial, while McDonald's stock slips despite a multi-billion-dollar reinvestment plan.
Stocks like Expedia and AT&T are facing pressure due to investor concerns that Meta's new Muse AI platform will disrupt their traditional consumer business models.
Immunovant has halted the development of its lead candidate, imeroprubart, for the treatment of skin lupus after the drug failed to achieve success in a recent clinical trial.